NeuroSense Therapeutics Ltd.
NRSN
$1.08
-$0.72-40.00%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | -12.00% | -47.14% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | 8.01% | -17.53% | |
| Operating Income | -- | -- | -8.01% | 17.53% | |
| Income Before Tax | -- | -- | 12.87% | 6.72% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | 12.87% | 6.72% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | 12.87% | 6.72% | |
| EBIT | -- | -- | -8.01% | 17.53% | |
| EBITDA | -- | -- | -8.11% | 17.49% | |
| EPS Basic | -- | -- | 22.42% | 12.34% | |
| Normalized Basic EPS | -- | -- | 20.09% | -6.80% | |
| EPS Diluted | -- | -- | 22.42% | 12.34% | |
| Normalized Diluted EPS | -- | -- | 20.09% | -6.80% | |
| Average Basic Shares Outstanding | -- | -- | 17.75% | 16.31% | |
| Average Diluted Shares Outstanding | -- | -- | 17.75% | 16.31% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |